|
DE3812225A1
(de)
|
1988-04-13 |
1989-10-26 |
Basf Ag |
Isoxazol(isothiazol)-5-carbonsaeureamide
|
|
WO1997005131A1
(en)
|
1995-08-02 |
1997-02-13 |
J. Uriach & Cia. S.A. |
New carboxamides with antifungal activity
|
|
DE69628705T2
(de)
|
1995-08-24 |
2004-05-13 |
Basf Ag |
Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
|
|
PT957099E
(pt)
|
1998-04-15 |
2003-02-28 |
Pfizer Prod Inc |
Carboxamidas heterociclicas
|
|
AU2001273040A1
(en)
|
2000-06-27 |
2002-01-08 |
Du Pont Pharmaceuticals Company |
Factor xa inhibitors
|
|
AU2003234464B2
(en)
|
2002-05-03 |
2009-06-04 |
Exelixis, Inc. |
Protein kinase modulators and methods of use
|
|
US7598412B2
(en)
|
2003-10-08 |
2009-10-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CN101675928A
(zh)
|
2003-11-14 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
|
|
WO2005077345A1
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Compounds for the treatment of gastro-esophageal reflux disease
|
|
WO2005077373A2
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Treatment of gastro-esophageal reflux disease (gerd)
|
|
JP2008503446A
(ja)
|
2004-05-06 |
2008-02-07 |
プレキシコン，インコーポレーテッド |
Ｐｄｅ４ｂ阻害剤及びその使用
|
|
SE0401969D0
(sv)
|
2004-08-02 |
2004-08-02 |
Astrazeneca Ab |
Piperidine derivatives
|
|
US20060100226A1
(en)
|
2004-09-10 |
2006-05-11 |
Sikorski James A |
2-Thiopyrimidinones as therapeutic agents
|
|
DE102004051277A1
(de)
|
2004-10-21 |
2006-04-27 |
Merck Patent Gmbh |
Heterocyclische Carbonylverbindungen
|
|
JP2006176443A
(ja)
|
2004-12-22 |
2006-07-06 |
Shionogi & Co Ltd |
メラニン凝集ホルモン受容体アンタゴニスト
|
|
ATE488496T1
(de)
|
2005-06-22 |
2010-12-15 |
Pfizer Prod Inc |
Histamin-3-rezeptorantagonisten
|
|
JP4822406B2
(ja)
|
2005-09-26 |
2011-11-24 |
ルネサスエレクトロニクス株式会社 |
表示制御駆動装置および表示システム
|
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
|
KR101394245B1
(ko)
|
2005-12-30 |
2014-05-14 |
에스케이바이오팜 주식회사 |
아이속사졸 유도체 및 이의 용도
|
|
WO2007086584A1
(ja)
|
2006-01-30 |
2007-08-02 |
Meiji Seika Kaisha, Ltd. |
新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
|
|
TW200815351A
(en)
|
2006-05-02 |
2008-04-01 |
Astrazeneca Ab |
Novel compounds
|
|
WO2008046072A2
(en)
|
2006-10-13 |
2008-04-17 |
The Board Of Regents Of The University Of Texas System |
Chemical inducers of neurogenesis
|
|
US8193225B2
(en)
|
2006-10-13 |
2012-06-05 |
The Board Of Regents Of The University Of Texas System |
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
|
|
EP2076513A1
(en)
|
2006-10-20 |
2009-07-08 |
Irm Llc |
Compositions and methods for modulating c-kit and pdgfr receptors
|
|
WO2008070739A1
(en)
|
2006-12-06 |
2008-06-12 |
Cytokinetics, Inc. |
Ksp activators
|
|
CN101778845B
(zh)
|
2007-06-29 |
2014-06-25 |
爱思开生物制药株式会社 |
用于预防和治疗再狭窄的包含异噁唑衍生物的药物组合物
|
|
WO2009011850A2
(en)
|
2007-07-16 |
2009-01-22 |
Abbott Laboratories |
Novel therapeutic compounds
|
|
CN101796036A
(zh)
|
2007-08-02 |
2010-08-04 |
欧加农股份有限公司 |
作为trpv1调节剂的5-苯基异噁唑-3-甲酰胺衍生物
|
|
AU2008345225A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
US8236838B2
(en)
|
2008-04-21 |
2012-08-07 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
|
US20090318429A1
(en)
|
2008-04-28 |
2009-12-24 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
|
|
US20120095002A1
(en)
|
2009-02-04 |
2012-04-19 |
N.V. Organon |
Isoxazole-5-carboxamide derivatives
|
|
CA2755120C
(en)
|
2009-03-11 |
2017-05-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
|
SI3330255T1
(sl)
*
|
2009-03-20 |
2021-03-31 |
Vertex Pharmaceuticals Incorporated |
Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
|
|
GB0910003D0
(en)
|
2009-06-11 |
2009-07-22 |
Univ Leuven Kath |
Novel compounds for the treatment of neurodegenerative diseases
|
|
IN2012DN00352A
(enExample)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
|
WO2011008931A2
(en)
|
2009-07-15 |
2011-01-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
|
|
US9212177B2
(en)
|
2009-08-05 |
2015-12-15 |
Versitech Limited |
Antiviral compounds and methods of making and using thereof
|
|
GB2474120B
(en)
|
2009-10-01 |
2011-12-21 |
Amira Pharmaceuticals Inc |
Compounds as Lysophosphatidic acid receptor antagonists
|
|
US8569899B2
(en)
|
2009-12-30 |
2013-10-29 |
Stmicroelectronics, Inc. |
Device and method for alignment of vertically stacked wafers and die
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
WO2011133953A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
EP2593447B1
(de)
|
2010-07-15 |
2016-08-17 |
Bayer Intellectual Property GmbH |
3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
|
|
TR201807311T4
(tr)
|
2011-03-10 |
2018-06-21 |
Daiichi Sankyo Co Ltd |
Dispiropirolidin derivesi.
|
|
CA2736441A1
(en)
|
2011-04-06 |
2012-10-06 |
The Regents Of The University Of California |
Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
|
|
HUE047354T2
(hu)
*
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
|
ME03652B
(me)
*
|
2011-05-18 |
2020-07-20 |
Vertex Pharmaceuticals Europe Ltd |
Deuterisani derivati ivakaftora
|
|
EA201490406A1
(ru)
|
2011-07-29 |
2014-07-30 |
Кариофарм Терапевтикс, Инк. |
Модуляторы ядерного транспорта и их применение
|
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
Ｎ−置換ヘテロシクリルカルボキサミド類
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
US8623860B2
(en)
|
2011-12-30 |
2014-01-07 |
Boehringer Ingelheim International Gmbh |
Azetidine derivatives, pharmaceutical compositions and uses thereof
|
|
AU2013221420B2
(en)
|
2012-02-16 |
2017-07-13 |
Corteva Agriscience Llc |
Methods of producing sulfilimine compounds
|
|
UA110436C2
(en)
|
2012-03-06 |
2015-12-25 |
Zoetis Llc |
Antibacterial phenol compounds
|
|
WO2013146970A1
(ja)
|
2012-03-29 |
2013-10-03 |
第一三共株式会社 |
新規キノリン誘導体
|
|
JP6746313B2
(ja)
|
2012-08-01 |
2020-08-26 |
ユナイテッド セラピューティクス コーポレイション |
プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
|
|
AU2013319788B2
(en)
|
2012-09-24 |
2019-04-11 |
Yissum Reasearch Development Company of the Hebrew University Of Jerusalem Ltd. |
Restoration of the CFTR function by splicing modulation
|
|
US9676779B2
(en)
|
2012-11-20 |
2017-06-13 |
Discoverybiomed, Inc. |
Small molecule CFTR correctors
|
|
CA2891965A1
(en)
|
2012-11-20 |
2014-05-30 |
Discoverybiomed, Inc. |
Small molecule bicyclic and tricyclic cftr correctors
|
|
CN109364075B
(zh)
*
|
2012-11-21 |
2021-10-29 |
顶点制药（欧洲）有限公司 |
氘化cftr增效剂
|
|
EP2968323A4
(en)
|
2013-03-13 |
2016-12-14 |
Flatley Discovery Lab |
PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
EP2968285A4
(en)
|
2013-03-13 |
2016-12-21 |
Flatley Discovery Lab |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
EP2968987A4
(en)
|
2013-03-15 |
2017-04-26 |
Vertex Pharmaceuticals Inc. |
Correctors acting through msd1 of cftr protein
|
|
CA2903103C
(en)
|
2013-03-15 |
2020-06-09 |
Discoverybiomed, Inc. |
Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
|
|
WO2014176553A1
(en)
|
2013-04-26 |
2014-10-30 |
Vertex Pharmaceuticals Incorporated |
Correctors acting through msd1 of cftr protein
|
|
CA3122383A1
(en)
|
2013-05-07 |
2014-11-13 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
|
|
WO2014181287A1
(en)
|
2013-05-09 |
2014-11-13 |
Piramal Enterprises Limited |
Heterocyclyl compounds and uses thereof
|
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
|
US9920073B2
(en)
|
2013-10-04 |
2018-03-20 |
Drexel University |
Compositions useful for inhibiting HIV-1 infection and methods using same
|
|
CA2942386A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
AU2015229117A1
(en)
|
2014-03-13 |
2016-09-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
|
EP3157917B1
(en)
|
2014-06-19 |
2020-03-18 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
|
WO2016054560A1
(en)
|
2014-10-02 |
2016-04-07 |
Flatley Discovery Lab |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
WO2016105477A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US10738011B2
(en)
|
2014-12-23 |
2020-08-11 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
US10548878B2
(en)
|
2015-07-24 |
2020-02-04 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods of increasing CFTR activity
|
|
US20190022071A1
(en)
|
2015-08-31 |
2019-01-24 |
Proteostasis Therapeutics, Inc. |
Methods of treating pulmonary diseases and disorders
|
|
SG11201802798WA
(en)
|
2015-10-06 |
2018-05-30 |
Proteostasis Therapeutics Inc |
Compounds, compositions, and methods for modulating cftr
|
|
MA44126A
(fr)
|
2015-12-22 |
2018-10-31 |
Proteostasis Therapeutics Inc |
Méthodes de traitement de maladies et troubles pulmonaires
|
|
WO2017177124A1
(en)
|
2016-04-07 |
2017-10-12 |
Proteostasis Therapeutics, Inc. |
Silicone atoms containing ivacaftor analogues
|
|
AU2017264612A1
(en)
|
2016-05-09 |
2018-11-22 |
Proteostasis Therapeutics, Inc. |
Methods of identifying CFTR modulators
|
|
ES2954658T3
(es)
|
2016-06-21 |
2023-11-23 |
Proteostasis Therapeutics Inc |
Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
|